An in vivo molecular response analysis of colorectal cancer treated with Astragalus membranaceus extract

Ailun Tseng1, Chih-Hsueh Yang2, Chih-Hao Chen1

  • 1Institute of Systems Biology and Bioinformatics, National Central University, Taoyuan 320, Taiwan, R.O.C.

Oncology Reports
|January 1, 2016
PubMed

Insights

Astragalus membranaceus (AM), a traditional Chinese medicine, effectively inhibits colorectal cancer growth in mice. AM targets chromosome organization, histone modification, and macromolecule metabolism, offering a potential new therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Chemotherapy for colorectal cancer often leads to chemoresistance and side effects.
  • Novel therapeutic agents targeting molecular pathways are needed to overcome these limitations.

Purpose of the Study:

  • To investigate the antitumor effects of Astragalus membranaceus (AM) on colorectal cancer.
  • To elucidate the molecular mechanisms underlying AM's anti-tumorigenic activity.

Main Methods:

  • Assessed AM's anti-tumor effect on subcutaneous human colorectal cancer (HCT116) xenografts in nude mice.
  • Utilized microarray expression profiling to analyze gene and microRNA expression in tumors from AM-treated and control mice.

Main Results:

  • AM administration suppressed key biological processes including chromosome organization, histone modification, and macromolecule metabolic processes.
  • Differentially expressed microRNAs indicated involvement in macromolecule metabolism, intracellular transport, and cancer signaling pathways.
  • Gene expression profiles of AM were comparable to known natural chemopreventive agents.

Conclusions:

  • Astragalus membranaceus demonstrates significant in vivo anti-tumor efficacy against colorectal cancer.
  • AM exerts its effects by modulating critical cellular pathways involved in cancer progression.
  • AM represents a promising candidate for a novel therapeutic drug in colorectal cancer treatment.

Related Concept Videos